The incidence of hypoglycaemia was higher with glimepiride than with linagliptin ( 36.1 vs. 7.5 % ; p < 0.0001 ) ; after performing sensitivity analyses by excluding events during dose escalation ( weeks0-16 ) , this difference remained significant ( weeks16-104 : 25.8 vs. 5.9 % ; p < 0.0001 ) .